Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Novel targets
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
BA211
Dual-indication*
> 10,000
HLA-A2+
TC11
αCD3 TCE
DC Selected
IND
2026
2H27
BA225
Multi-indication*
> 60,000
HLA-A2+
TC25
αCD3 TCE
DC Selection
IND
2H26
1H28
Multiple
> 60,000
Pan-HLA+
Undisclosed
DC Selection
IND
2027
2028
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
Autoimmune
program
Multiple Autoimmune Indications
Multiple HLA Options
Undisclosed
Discovery
Other targets
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
BA202
BA201
BA2401
20,000-40,000
PRAME A2
MAGE-A4/A8
PRAME A24
Lead Selection
Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Novel targets
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
BA211
Dual-indication*
> 10,000
HLA-A2+
TC11
αCD3 TCE
DC Selected
IND
2026
2H27
BA225
Multi-indication*
> 60,000
HLA-A2+
TC25
αCD3 TCE
DC Selection
IND
2H26
1H28
Multiple
> 60,000
Pan-HLA+
Undisclosed
DC Selection
IND
2027
2028
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
Autoimmune
program
Multiple Autoimmune Indications
Multiple HLA Options
Undisclosed
Discovery
Other targets
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
BA202
BA201
BA2401
20,000-40,000
PRAME A2
MAGE-A4/A8
PRAME A24
Lead Selection
Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Novel targets
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
BA211
Dual-indication*
> 10,000
HLA-A2+
TC11
αCD3 TCE
DC Selected
IND
2026
2H27
BA225
Multi-indication*
> 60,000
HLA-A2+
TC25
αCD3 TCE
DC Selection
IND
2H26
1H28
Multiple
> 60,000
Pan-HLA+
Undisclosed
DC Selection
IND
2027
2028
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
Autoimmune
program
Multiple Autoimmune Indications
Multiple HLA Options
Undisclosed
Discovery
Other targets
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
Solid tumor
program
Annual addressable metastatic US patients
Target and engager
Discovery
Lead optimisation
IND enabling
Status
BA202
BA201
BA2401
20,000-40,000
PRAME A2
MAGE-A4/A8
PRAME A24
Lead Selection
Novel targets
BA211
Dual-indication*
DC Selection
DC Selected
IND
2026
DC 2026
2027
IND 2H27
2H27
> 10,000
HLA-A2+ US patients
> 10,000
HLA-A2+
> 10,000
HLA-A2+
TC11
αCD3 TCE
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Solid tumor program
Pipeline
Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumours as well as autoimmune indications
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Other targets
Other targets
BA201
BA202
BA2401
BA202
BA201
BA2401
Discovery
Lead Selection
20-40k US patients
20,000-40,000
MAGE-A4/A8 HLA-A2
PRAME HLA-A2
PRAME HLA-A24
PRAME A2
MAGE-A4/A8
PRAME A24
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Solid tumor program
BA225
Multi-indication*
DC Selection
IND
2026
DC 2H26
2H26
2027
IND 1H28
1H28
> 60,000
HLA-A2+ US patients
> 60,000
HLA-A2+
> 60,000
HLA-A2+
TC25
Undisclosed
TC25
αCD3 TCE
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Target and engager
Solid tumor program
BA301
Multi-indication
Multiple
Autoimmune
Indications
Multiple Autoimmune Indications
Lead selection
Discovery
Autoimmune
Not HLA-restricted
Multiple HLA
Options
Multiple HLA Options
TC301
Undisclosed
Undisclosed
Annual addressable metastatic patients
Annual addressable metastatic US patients
Target and engager
Target and engager
Autoimmune program
Multiple
DC Selection
IND
2026
2027
2027
2028
DC 2026
DC 2027
IND 2027
IND 2028
> 60,000
HLA-A2+ US patients
> 60,000
HLA-A2+
> 60,000
HLA-A2+
Undisclosed
Annual addressable metastatic patients
Annual addressable metastatic US patients
Annual addressable metastatic US patients
Target and engager
Target and engager
Solid tumor program
*High potential indications for TCEs including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic